Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
2016 · Breast Cancer · 48 citations
https://doi.org/10.1007/s12282-016-0666-7
K
Katsuhiko Nakatsukasa
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
65
Papers
448
Citations
13
h-index
15
i10-index
Katsuhiko Nakatsukasa is an academic researcher from Kyoto Prefectural University. The author has contributed to research in topics: Cancer Treatment and Pharmacology & Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research. The author has an h-index of 13, co-authored 56 publications.
ORCID: 0000-0002-1411-1436Papers by this author
worksChange in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence
2015 · European Journal of Surgical Oncology · 16 citations
https://doi.org/10.1016/j.ejso.2015.01.030
Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer
2016 · Breast Cancer · 12 citations
https://doi.org/10.1007/s12282-016-0677-4
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
2021 · BMC Cancer · 4 citations
https://doi.org/10.1186/s12885-020-07746-9
[A case of multi-drug resistant recurrent breast cancer with multiple bone metastasis responding to TS-1 and trastuzumab].
2006 · PubMed · 1 citations
[Experience of Fulvestrant for Hormone Receptor-Positive HER2-Negative Advanced and Metastatic Breast Cancer].
2018 · PubMed · 1 citations
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat